Capricor Therapeutics Meets with FDA on DMD Cell Therapy

Summary

Capricor Therapeutics announced a regulatory update regarding its investigational cell therapy, Deramiocel, for Duchenne muscular dystrophy (DMD). Following a Type A meeting with the FDA, the company plans to submit data from the completed HOPE-3 pivotal trial to support its Biologics License Application (BLA) resubmission.StockTitan

Impact Analysis

So basically, Capricor is trying to turn the tide after the FDA’s Complete Response Letter (CRL) threw a wrench in their plans for Deramiocel. The Type A meeting with the FDA is a critical step, suggesting the agency is open to collaboration and flexibility, which is a positive signal for Capricor’s resubmission strategy.StockTitan The interesting part isn’t just the resubmission; it’s the timing of the HOPE-3 trial data expected in Q4 2025, which could be pivotal in addressing the FDA’s concerns.StockTitan Analysts like Joseph Pantginis are optimistic, issuing a Buy rating, which indicates confidence in Capricor’s ability to navigate these regulatory hurdles.Tip Ranks+ 2 However, the looming class action lawsuit for alleged securities fraud adds a layer of risk that could impact investor sentiment.Reuters+ 2 The market might be underestimating the potential for a successful resubmission, but the legal issues could be a wildcard.